Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Prospective cohort study of patients with stage III colorectal cancer aged ≥ 80 years who underwent curative resection: The HiSCO-04 study.
Authors
Manabu Shimomura Sr.
Hiroshima University, Hiroshima-Shi Minami-Ku, Japan;
Manabu Shimomura Sr., Satoshi Ikeda , Masahiro Nakahara , Tomohiro Adachi , Yasufumi Saitoh , Yosuke Shimizu , Kazuhiro Toyota , Yasuyo Ishizaki , Masanori Yoshimitsu , Yuji Takakura , Wataru Shimizu , Daisuke Sumitani , Shinya Kodama , Masahiko Fujimori , Mamoru Oeda , Hironori Kobayashi , Hideki Ohdan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 102)
DOI
10.1200/JCO.2023.41.4_suppl.102
Abstract #
102
Poster Bd #
E19
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.
First Author: Naohiro Tomita
Poster
2015 ASCO Annual Meeting
S-1 as adjuvant chemotherapy for stage III colon cancer: Updated outcomes of ACTS-CC trial.
First Author: Yusuke Kinugasa
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant chemotherapy for older patients with stage II/III gastric cancer: A retrospective cohort study.
First Author: Yu-Hsuan Shih
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 2 multi-institutional prospective feasibility study of uracil-tegafur and leucovorin as adjuvant chemotherapy for patients aged 80 years or more after curative resection of colorectal cancer: The HiSCO-03 study.
First Author: Masashi Miguchi Sr.